# EDGAR Filing Document

**Accession Number:** 0001778922
**File Stem:** 0001193125-26-051323
**Filing Date:** 2026-2
**Character Count:** 20932
**Document Hash:** 261e8200d1c88cc94e87a865194619c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-051323.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001193125-26-051323

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SpyGlass Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001778922
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 833044245
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95481
- **FILM NUMBER:** 26632524

**BUSINESS ADDRESS:**
- **STREET 1:** 27081 ALISO CREEK ROAD
- **STREET 2:** SUITE 125
- **CITY:** ALISO VIEJO
- **STATE:** CA
- **ZIP:** 92656
- **BUSINESS PHONE:** 949-284-6904

**MAIL ADDRESS:**
- **STREET 1:** 27081 ALISO CREEK ROAD
- **STREET 2:** SUITE 125
- **CITY:** ALISO VIEJO
- **STATE:** CA
- **ZIP:** 92656

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SpyGlassPharma, Inc.
- **DATE OF NAME CHANGE:** 20230711

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SpyGlass Ophthalmics, Inc.
- **DATE OF NAME CHANGE:** 20190605
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Gilde Healthcare Holding B.V.
- **CENTRAL INDEX KEY:** 0001420106

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NEWTONLAAN 91
- **STREET 2:** PO BOX 85067
- **CITY:** 3508 UTRECHT
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31(0)30-2192549

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NEWTONLAAN 91
- **STREET 2:** PO BOX 85067
- **CITY:** 3508 UTRECHT
- **PROVINCE COUNTRY:** P7

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex1.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**SpyGlass Pharma, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.00001 per share**

*(Title of Class of Securities)*

**85220G109**

*(CUSIP Number)*

**Gilde Healthcare Holding B.V.**<br>Stadsplateau 36<br>Attention: Edwin de Graaf<br>Utrecht P7 3521 AZ<br>31 30 219 2565

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/09/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **85220G109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Gilde Healthcare Holding B.V.** | Name of reporting person<br>**Gilde Healthcare Holding B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2187513.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2187513.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.57%** | Percent of class represented by amount in Row (11)<br>**6.57%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **85220G109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Gilde Healthcare VG VI Management B.V.** | Name of reporting person<br>**Gilde Healthcare VG VI Management B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2187513.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2187513.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.57%** | Percent of class represented by amount in Row (11)<br>**6.57%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **85220G109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Cooperatieve Gilde Healthcare VG VI U.A.** | Name of reporting person<br>**Cooperatieve Gilde Healthcare VG VI U.A.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2187513.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2187513.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.57%** | Percent of class represented by amount in Row (11)<br>**6.57%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **85220G109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Manapouri B.V.** | Name of reporting person<br>**Manapouri B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2187513.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2187513.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.57%** | Percent of class represented by amount in Row (11)<br>**6.57%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **85220G109** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Martemanshurk B.V.** | Name of reporting person<br>**Martemanshurk B.V.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**P7** | Citizenship or place of organization<br>**P7** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2187513.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2187513.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | Aggregate amount beneficially owned by each reporting person<br>**2187513.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**6.57%** | Percent of class represented by amount in Row (11)<br>**6.57%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.00001 per share

**(b) Name of Issuer:**
SpyGlass Pharma, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
27061 Aliso Creek Rd, Suite 100, Aliso Viejo, CA, 92656

This joint statement on Schedule 13D (this "Statement") is filed with respect to the common stock, par value $0.00001 per share ("Common Stock"), of SpyGlass Pharma, Inc., a Delaware corporation (the "Issuer"). Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

**Item 4. Purpose of Transaction**

The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise.

Geoff Pardo, a partner at Gilde Healthcare, serves as a member of the board of directors of the Issuer. In addition, in his capacity as a director, Mr. Pardo may be entitled to receive cash compensation and equity compensation, including stock options, restricted stock units or other equity awards, pursuant to a plan or policy with regard to compensation of members of the board of directors of the Issuer.

Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
According to the Issuer's Rule 424(b)(4) Prospectus, dated February 5, 2026 and filed with the Securities and Exchange Commission ("SEC") on February 6, 2026, there were 33,317,414 shares of Common Stock outstanding after the closing of the Offering.

Gilde Healthcare is the record holder of an aggregate of 2,187,513 shares of Common Stock, which represents beneficial ownership of approximately 6.57% of the outstanding shares of Common Stock after the closing of the Offering.

Gilde Healthcare Management, as the manager of Gilde Healthcare, has the power to vote and dispose of securities held by Gilde Healthcare and may be deemed to beneficially own the securities held of record by Gilde Healthcare. Gilde Healthcare Management is owned by GHH. The managing partners of GHH are Manapouri B.V. and Martemanshurk B.V.

As a result, each of the Reporting Persons may beneficially own an aggregate of 2,187,513 shares of Common Stock, or approximately 6.57% of the outstanding Common Stock.

**(b)**
Each Reporting Person has shared power to vote and dispose of 2,187,513 shares of Common Stock.

**(c)**
Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Items 3 and 4 of this Statement is incorporated herein by reference. In connection with its purchase of shares of the Issuer's preferred stock, Gilde Healthcare and certain of the Issuer's other investors are party to an Amended and Restated Investors' Rights Agreement, dated May 30, 2025, with the Issuer (the "Investors' Rights Agreement"). After the closing of the Offering, the stockholders party thereto are entitled to certain registration rights, including the right to demand that that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing. The terms and provisions of the Investors' Rights Agreement are described more fully in the Issuer's Registration Statement on Form S-1 (File No. 333-292779) declared effective by the Commission on January 16, 2026 (the "Registration Statement"), and the above summary is qualified by reference to such description and the full text of the Investors' Rights Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference.

In connection with the Offering, Gilde Healthcare entered into a lock-up agreement, pursuant to which Gilde Healthcare agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuer's securities held by Gilde Healthcare for 180 days following February 5, 2026. The terms and provisions of such lock-up agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 3 to this Statement and is incorporated herein by reference.

Upon consummation of the Offering, the Issuer entered into an indemnification agreement with each of its directors, including Mr. Pardo. The indemnification agreement requires the Issuer, among other things, to indemnify Mr. Pardo against liabilities that may arise by reason of his status or service. The indemnification agreement also requires the Issuer to advance all expenses reasonably and actually incurred by Mr. Pardo in investigating or defending any such action, suit or proceeding. The terms and provisions of the indemnification agreement are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the indemnification agreement, a form of which is filed as Exhibit 4 to this Statement and is incorporated herein by reference.

Mr. Pardo, in his capacity as director, may be entitled to receive cash compensation and equity compensation, including stock options, restricted stock units or other equity awards pursuant to a plan or policy with regard to compensation of members of the board of directors of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Gilde Healthcare Holding B.V.

**Signature:** /s/ Edwin de Graaf

**Name/Title:** Edwin de Graaf/Managing Director

**Date:** 02/13/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Gilde Healthcare VG VI Management B.V.

**Signature:** /s/ Edwin de Graaf

**Name/Title:** Edwin de Graaf/Managing Director

**Date:** 02/13/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Cooperatieve Gilde Healthcare VG VI U.A.

**Signature:** /s/ Edwin de Graaf

**Name/Title:** Edwin de Graaf/Managing Director of Gilde Healthcare VG VI Management B.V., as Manager of Cooperatieve Gilde Healthcare VG VI U.A.

**Date:** 02/13/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Manapouri B.V.

**Signature:** /s/ Edwin de Graaf

**Name/Title:** Edwin de Graaf/Managing Director

**Date:** 02/13/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Martemanshurk B.V.

**Signature:** /s/ Pieter van der Meer

**Name/Title:** Pieter van der Meer/Managing Director

**Date:** 02/13/2026